Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 113; no. 38; pp. 10672 - 10677
• Main Authors: Jung, Seung-Hyun, Kim, Min Sung, Lee, Sung-Hak, Park, Hyun-Chun, Choi, Hyun Joo, Maeng, Leeso, Min, Ki Ouk, Kim, Jeana, Park, Tae In, Shin, Ok Ran, Kim, Tae-Jung, Xu, Haidong, Lee, Kyo Young, Kim, Tae-Min, Song, Sang Yong, Lee, Charles, Chung, Yeun-Jun, Lee, Sug Hyung
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 20.09.2016
• Subjects: Adolescent; Adult; Aged; beta Catenin - genetics; Biological Sciences; Exome - genetics; Female; Genome, Human; Genomics; Histiocytoma, Benign Fibrous - genetics; Histiocytoma, Benign Fibrous - pathology; Humans; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Medical diagnosis; Middle Aged; Mutation; Oncology; Proto-Oncogene Proteins c-akt - genetics; Tumorigenesis; Tumors; Whole Exome Sequencing; copy number alteration; AKT1 mutation; pulmonary sclerosing hemangioma; whole-exome sequencing
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1606946113

Pulmonary sclerosing hemangioma (PSH) is a benign tumor with two cell populations (epithelial and stromal cells), for which genomic profiles remain unknown. We conducted exome sequencing of 44 PSHs and identified recurrent somatic mutations of AKT1 (43.2%) and β-catenin (4.5%). We used a second subset of 24 PSHs to confirm the high frequency of AKT1 mutations (overall 31/68, 45.6%; p.E17K, 33.8%) and recurrent β-catenin mutations (overall 3 of 68, 4.4%). Of the PSHs without AKT1 mutations, two exhibited AKT1 copy gain. AKT1 mutations existed in both epithelial and stromal cells. In two separate PSHs from one patient, we observed two different AKT1 mutations, indicating they were not disseminated but independent arising tumors. Because the AKT1 mutations were not found to cooccur with β-catenin mutations (or any other known driver alterations) in any of the PSHs studied, we speculate that this may be the single-most common driver alteration to develop PSHs. Our study revealed genomic differences between PSHs and lung adenocarcinomas, including a high rate of AKT1 mutation in PSHs. These genomic features of PSH identified in the present study provide clues to understanding the biology of PSH and for differential genomic diagnosis of lung tumors.